Literature DB >> 18497953

The overexpression of c-met as a prognostic indicator for gastric carcinoma compared to p53 and p21 nuclear accumulation.

Uta Drebber1, Stephan E Baldus, Britt Nolden, Guido Grass, Elfriede Bollschweiler, Hans P Dienes, Arnulf H Hölscher, Stefan P Mönig.   

Abstract

The purpose of this study was to clarify the relationship of the immunohistochemical expression of c-met, p53 and p21 with clinicopathological parameters and prognosis in gastric carcinomas. We analyzed specimens from 114 gastric cancer patients (median age 64 years, range: 33-86) who underwent gastrectomy with lymphadenectomy. Specimens were categorized according to the tumor differentiation, based on UICC, WHO, Laurén, Ming and Goseki classifications. Specimens were examined immunohistochemically with antibodies against c-met, p53 and p21. The expression was evaluated semiquantitatively and correlated with the clinicopathological parameters. The c-met staining pattern was positive in 73.7%. P53 and p21 were positive in 86.8 and 67.5%, respectively. No significant correlation between c-met or p21 expression and the clinicopathological parameters was seen. A significant increase of p53 expression was observed in stage pT3 and -4. The overexpression of c-met and p53 was significantly associated with a poor prognosis in the univariate survival analysis. In the multivariate analysis this impact was maintained for c-met. P21 proved to be a significant prognostic factor in the multivariate analysis. Our data suggest that the overexpression of c-met and p21 may represent independent prognostic factors in gastric carcinoma.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18497953

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  40 in total

1.  Lentivirus-mediated RNA silencing of c-Met markedly suppresses peritoneal dissemination of gastric cancer in vitro and in vivo.

Authors:  Xiao-lei Wang; Xi-mei Chen; Jian-ping Fang; Chang-qin Yang
Journal:  Acta Pharmacol Sin       Date:  2012-03-12       Impact factor: 6.150

2.  The prognostic significance of p53 expression in gastric cancer: a meta-analysis.

Authors:  Kongkong Wei; Lei Jiang; Yaoyao Wei; Yufeng Wang; Xuankun Qian; Qiang Dai; Quanlin Guan
Journal:  J Cancer Res Clin Oncol       Date:  2014-10-15       Impact factor: 4.553

3.  Energetic factors determining the binding of type I inhibitors to c-Met kinase: experimental studies and quantum mechanical calculations.

Authors:  Zhe Yu; Yu-chi Ma; Jing Ai; Dan-qi Chen; Dong-mei Zhao; Xin Wang; Yue-lei Chen; Mei-yu Geng; Bing Xiong; Mao-sheng Cheng; Jing-Kang Shen
Journal:  Acta Pharmacol Sin       Date:  2013-09-23       Impact factor: 6.150

Review 4.  Personalized and precision medicine: integrating genomics into treatment decisions in gastrointestinal malignancies.

Authors:  Trang H Au; Kai Wang; David Stenehjem; Ignacio Garrido-Laguna
Journal:  J Gastrointest Oncol       Date:  2017-06

5.  Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a randomised, double-blind, placebo-controlled, phase 3 trial.

Authors:  Daniel V T Catenacci; Niall C Tebbutt; Irina Davidenko; André M Murad; Salah-Eddin Al-Batran; David H Ilson; Sergei Tjulandin; Evengy Gotovkin; Boguslawa Karaszewska; Igor Bondarenko; Mohamedtaki A Tejani; Anghel A Udrea; Mustapha Tehfe; Ferdinando De Vita; Cheryl Turkington; Rui Tang; Agnes Ang; Yilong Zhang; Tien Hoang; Roger Sidhu; David Cunningham
Journal:  Lancet Oncol       Date:  2017-09-25       Impact factor: 41.316

6.  Adjuvant chemotherapy, p53, carcinoembryonic antigen expression and prognosis after D2 gastrectomy for gastric adenocarcinoma.

Authors:  Ming-Ming He; Dong-Sheng Zhang; Feng Wang; Zhi-Qiang Wang; Hui-Yan Luo; Chao Ren; Ying Jin; Dong-Liang Chen; Rui-Hua Xu
Journal:  World J Gastroenterol       Date:  2014-01-07       Impact factor: 5.742

Review 7.  Genomic and genetic alterations influence the progression of gastric cancer.

Authors:  Stefania Nobili; Lorenzo Bruno; Ida Landini; Cristina Napoli; Paolo Bechi; Francesco Tonelli; Carlos A Rubio; Enrico Mini; Gabriella Nesi
Journal:  World J Gastroenterol       Date:  2011-01-21       Impact factor: 5.742

8.  Correlation between expression of p53, p21/WAF1, and MDM2 proteins and their prognostic significance in primary hepatocellular carcinoma.

Authors:  Mei-Fang Zhang; Zhi-Yi Zhang; Jia Fu; Yu-Feng Yang; Jing-Ping Yun
Journal:  J Transl Med       Date:  2009-12-22       Impact factor: 5.531

9.  Over-expression of Metastasis-associated in Colon Cancer-1 (MACC1) Associates with Better Prognosis of Gastric Cancer Patients.

Authors:  Shao-Hua Ge; Xiao-Jiang Wu; Xiao-Hong Wang; Xiao-Fang Xing; Lian-Hai Zhang; Yu-Bing Zhu; Hong Du; Bin Dong; Ying Hu; Jia-Fu Ji
Journal:  Chin J Cancer Res       Date:  2011-06       Impact factor: 5.087

10.  Role of c-Met in cancer: emphasis on lung cancer.

Authors:  Ravi Salgia
Journal:  Semin Oncol       Date:  2009-04       Impact factor: 4.929

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.